Insulet Corp. (PODD) on Decifer

Decifer ranks PODD number 134 of 269 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 31% a year, faster than 81 in 100 companies we measure.
• It keeps about 13 cents of every sales dollar as cash, safer than 72 in 100 companies we measure.
• It earns about 14% a year on the money put into the business, better than 72 in 100 companies we measure.
• It costs about 28 times its yearly profit; the middle of its industry is 31. Cheaper than 62 in 100 companies we measure, against their own industries.

The current read

The evidence on PODD points in two directions at once: the intelligence feed flags this name as connected to what is moving markets now, while a live market force pressures this name through its theme connection. Until one side gives way, treat the picture as unresolved rather than a clean story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full PODD research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.